Navigation Links
Lilly Announces Changes in Key Leadership Roles
Date:5/21/2008

m the company, which has also led to changes in the management structure.

Tim Franson, M.D., vice president of global regulatory affairs, will retire from the company after 22 years of service. Franson is a diplomat of the American Board of Internal Medicine, a Fellow of the American College of Physicians and the Infectious Diseases Society of America, and played a leadership role on behalf of both Lilly and the industry in the reshaping of the Prescription Drug User Fee Act. He has held roles of increasing responsibility throughout his career at Lilly, including positions in medical (both in the U.S. and in Europe), health economics research and decision sciences, clinical research, and regulatory affairs. He has held his current position since 2003.

Alan Breier, M.D., vice president of medical and chief medical officer, has been appointed full professor in the department of psychiatry at the Indiana University School of Medicine after an 11-year career at Lilly. Breier, who joined Lilly in 1997 from the National Institutes of Health (NIH), has published more than 235 scientific articles in areas related to the cause and treatment of severe mental illnesses, and last year was honored by the American Psychiatric Association for excellence in medical student education. Breier has held a variety of leadership roles at Lilly on the Zyprexa(R) product team as well as in medical, and has served as the chief medical officer since 2003.

"Both Tim and Alan have provided exceptional leadership on behalf of our company and wise counsel to me personally. Their contributions to our organization and to the patients we serve have been very significant, and they will both be missed. Our deepest thanks and best wishes go with both of them as they embark on new endeavors," said Steve Paul, M.D., executive vice president of science and technology and president of LRL.

The primary change to the LRL structure is the creation of a combined global regulatory,
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... (April 21, 2014) -- A group of scientists ... and the Sanders-Brown Center on Aging has found ... and neuropsychological function in Parkinson,s disease (PD). ... , the study, which assessed cognitive function in ... the dopamine replacement therapy commonly used to treat ...
(Date:4/18/2014)... The Gerontologist reports that among older Christians, ... in anxiety about death and increases in life satisfaction, ... particular, listening to gospel music is associated with a ... sense of control. , These associations are similar for ... both low- and high-socioeconomic status. , The article, titled ...
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2
... Hopkins and elsewhere report what is believed to be ... inflammation of heart tissue and the subsequent damage leading ... latest findings from the Multiethnic Study of Atherosclerosis (MESA), ... the Journal of the American College of Cardiology, appear ...
... at Mattel Children,s Hospital UCLA have found that low-dose antidepressant ... adolescents suffering from irritable bowel syndrome, or IBS. ... students and 14 percent of high school kids in the ... the May issue of the peer-reviewed Journal of Pediatrics, is ...
... WASHINGTON, May 1 Speaker Nancy Pelosi today,released ... Information,Nondiscrimination Act, which the House passed this afternoon ... bill, which would prohibit health,insurance companies and employers ... test results, now goes to the President,s desk ...
... said today that there are more than 36,000 uninsured ... whom are on a waiting,list to receive health care ... a plan to help them gain access to health ... live with the,very real fear that a sudden illness ...
... Courage Center has received a,one-year grant of $150,000 ... to,support The Bridge to Independence. This coordinated campaign ... children with disabilities,through effective grassroots community organizing, policy ... leading member of the Minnesota Consortium of Citizens ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... present key scientific data on its Attention Deficit ... system and the investigational non-stimulant treatment under FDA ... Association (APA) annual meeting to be held May ...
Cached Medicine News:Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Antidepressant found to alleviate symptoms of irritable bowel syndrome in adolescents 2Health News:Pelosi: 'Genetic Information Nondiscrimination Act Will Protect Americans from Misuse of Genetic Information' 2Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 2Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 3Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 4Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 5Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 6Health News:Courage Center Receives $150,000 Grant From Minneapolis Foundation 2Health News:Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... Pa. , Jan. 14, 2014 Dynamic Healthcare Services, ... announced today that it acquired Progressive Home Medical Equipment, Inc. ... 7, 2014. The terms of the acquisition were not disclosed. ... equipment ("DME") company providing a wide range of sleep, mobility, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 8, 2011 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... that they have initiated the first of two Phase ... VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent ... treatment of Diabetic Macular Edema (DME).  The companies are ...
... (NASDAQ: IDIX ), a biopharmaceutical company engaged in ... human viral diseases, today announced that it has commenced an ... All of these shares are being sold by Idenix. ... book-running manager and underwriter for the offering. Idenix intends to ...
Cached Medicine Technology:Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 2Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 3Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 4Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 5Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 6Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock 2
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Medicine Products: